Skin Manifestations News

Skin Manifestations	Welcome, Profile Billing Logout

«1 2 345 6 7 »

||||||||||  methylprednisolone sodium succinate / Generic mfg.
Clinical:  A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. (clinicaltrials.gov) -  May 12, 2014
P3, N=36, Recruiting,  Sponsor: The Hospital for Sick Children
Trial completion date: Jan 2010 --> Jul 2015

|||||||||| New P1 trial: Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis (clinicaltrials.gov) - May 5, 2014
P1, N=890, Completed, Sponsor: Taro Pharmaceuticals USA

|||||||||| New P2 trial: Multiclear Treatment for Striae Distensae - A Pilot Study (clinicaltrials.gov) - Apr 27, 2014
P2, N=20, Not yet recruiting, Sponsor: National University Hospital, Singapore

|||||||||| Trial primary completion date: Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome (clinicaltrials.gov) - Apr 23, 2014
P4, N=16, Recruiting, Sponsor: Vanderbilt University
Trial completion date: Jan 2010 --> Jul 2015 Trial primary completion date: Feb 2013 --> Feb 2015

||||||||||  Octagam (intravenous normal human immunoglobulin) / Octapharma
Trial initiation date:  Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults (clinicaltrials.gov) -  Apr 6, 2014
P3, N=116, Completed,  Sponsor: Octapharma
Trial primary completion date: Feb 2013 --> Feb 2015 Initiation date: Jan 2006 --> Jun 2006

||||||||||  Doptelet (avatrombopag) / SOBI
Trial completion:  Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) (clinicaltrials.gov) -  Mar 30, 2014
P3, N=49, Completed,  Sponsor: Eisai Inc.
Initiation date: Jan 2006 --> Jun 2006 Active, not recruiting --> Completed

||||||||||  esomeprazole / Generic mfg.
Trial completion:  Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation (clinicaltrials.gov) -  Mar 25, 2014
P=N/A, N=369, Completed,  Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  linerixibat (GSK2330672) / GSK
Enrollment open:  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (clinicaltrials.gov) -  Mar 19, 2014
P1, N=40, Recruiting,  Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  Nplate (romiplostim) / Amgen, Kyowa Kirin
Clinical:  Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training (clinicaltrials.gov) -  Mar 11, 2014
P=N/A, N=40, Not yet recruiting,  Sponsor: Amgen

||||||||||  otesaconazole (VT-1161) / Mycovia Pharma
Enrollment closed:  A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis (clinicaltrials.gov) -  Mar 9, 2014
P2, N=48, Active, not recruiting,  Sponsor: Viamet Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting

||||||||||  Nplate (romiplostim) / Amgen, Kyowa Kirin
Enrollment change:  Safety Study of AMG 531 in Japanese Subjects With ITP (clinicaltrials.gov) -  Mar 4, 2014
P2, N=12, Completed,  Sponsor: Amgen
Recruiting --> Active, not recruiting N=16 --> 12

||||||||||  Tavalisse (fostamatinib) / Rigel
New P3 trial:  A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) -  Feb 27, 2014
P3, N=75, Not yet recruiting,  Sponsor: Rigel Pharmaceuticals

||||||||||  Tavalisse (fostamatinib) / Rigel
New P3 trial:  A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) -  Feb 27, 2014
P3, N=75, Not yet recruiting,  Sponsor: Rigel Pharmaceuticals

||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change:  PTTritux: Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) -  Feb 25, 2014
P2, N=12, Completed,  Sponsor: Assistance Publique - Hôpitaux de Paris
N=16 --> 12 N=10 --> 12

||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion:  PTTritux: Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) -  Feb 25, 2014
P2, N=12, Completed,  Sponsor: Assistance Publique - Hôpitaux de Paris
N=10 --> 12 Active, not recruiting --> Completed

|||||||||| Trial completion: Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D (clinicaltrials.gov) - Feb 22, 2014
P2, N=45, Completed, Sponsor: University of Aarhus
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  sertraline / Generic mfg.
Trial completion:  Treatment of Cholestatic Pruritus With Sertraline (clinicaltrials.gov) -  Feb 22, 2014
P2, N=40, Completed,  Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting --> Completed Recruiting --> Completed

||||||||||  Promacta (eltrombopag) / Novartis
Trial completion:  SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) -  Feb 22, 2014
P2, N=99, Completed,  Sponsor: GlaxoSmithKline
Recruiting --> Completed No longer recruiting --> Completed

||||||||||  cyclophosphamide / Generic mfg.
Trial completion:  Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease (clinicaltrials.gov) -  Feb 19, 2014
P2, N=32, Completed,  Sponsor: Johns Hopkins University
No longer recruiting --> Completed No longer recruiting --> Completed

||||||||||  Rituxan (rituximab) / Roche
Trial completion:  Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura (clinicaltrials.gov) -  Feb 19, 2014
P2, N=20, Completed,  Sponsor: University of Alabama at Birmingham
No longer recruiting --> Completed No longer recruiting --> Completed

||||||||||  Promacta (eltrombopag) / Novartis
Enrollment change:  PETIT2: Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (clinicaltrials.gov) -  Feb 19, 2014
P3, N=92, Completed,  Sponsor: GlaxoSmithKline
No longer recruiting --> Completed N=75 --> 92

||||||||||  Promacta (eltrombopag) / Novartis
Trial completion:  PETIT2: Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (clinicaltrials.gov) -  Feb 19, 2014
P3, N=92, Completed,  Sponsor: GlaxoSmithKline
N=75 --> 92 Active, not recruiting --> Completed

||||||||||  blisibimod (A-623) / Anthera Pharma
Trial initiation date:  MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP (clinicaltrials.gov) -  Jan 30, 2014
P2/3, N=60, Not yet recruiting,  Sponsor: Anthera Pharmaceuticals
Active, not recruiting --> Completed Initiation date: Dec 2013 --> Dec 2014

||||||||||  asivatrep (PAC-14028) / Amorepacific
New P2 trial:  Evaluation of the Antipruritic Effect of PAC-14028 Cream in Skin Pruritus (clinicaltrials.gov) -  Jan 30, 2014
P2, N=74, Completed,  Sponsor: Amorepacific Corporation

|||||||||| Trial completion, HEOR: Health-related Quality of Life and Fatigue in Adult Patients With Primary Immune Thrombocytopenic Purpura (pITP) (clinicaltrials.gov) - Jan 21, 2014
P=N/A, N=424, Completed, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Initiation date: Dec 2013 --> Dec 2014 Active, not recruiting --> Completed

|||||||||| Enrollment open: PTI PARI: Study of Immune Thrombocytopenia Pathogenesis: (clinicaltrials.gov) - Jan 19, 2014
P=N/A, N=175, Recruiting, Sponsor: Centre Hospitalier Universitaire Dijon
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  cetirizine oral / Generic mfg.
Trial initiation date:  Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching (clinicaltrials.gov) -  Jan 7, 2014
P4, N=73, Not yet recruiting,  Sponsor: Virginia Commonwealth University
Not yet recruiting --> Recruiting Initiation date: May 2013 --> Mar 2014

||||||||||  BI 655064 / AbbVie, Boehringer Ingelheim
Enrollment open:  Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) -  Jan 7, 2014
P1, N=10, Recruiting,  Sponsor: Boehringer Ingelheim
Initiation date: May 2013 --> Mar 2014 Not yet recruiting --> Recruiting

||||||||||  Promacta (eltrombopag) / Novartis
Trial completion:  Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT (clinicaltrials.gov) -  Jan 2, 2014
P2, N=30, Completed,  Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
Not yet recruiting --> Recruiting Recruiting --> Completed

|||||||||| Trial completion, Monotherapy: Evaluation of Fractional Bipolar Radiofrequency for the Treatment of Striae (clinicaltrials.gov) - Dec 29, 2013
P=N/A, N=22, Completed, Sponsor: Candela France
Recruiting --> Completed Recruiting --> Completed

|||||||||| Enrollment change: Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura (clinicaltrials.gov) - Dec 23, 2013
P=N/A, N=20, Completed, Sponsor: Samsung Medical Center
Recruiting --> Completed N=50 --> 20

|||||||||| Trial completion: Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura (clinicaltrials.gov) - Dec 23, 2013
P=N/A, N=20, Completed, Sponsor: Samsung Medical Center
N=50 --> 20 Recruiting --> Completed

|||||||||| Trial completion: Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis (clinicaltrials.gov) - Dec 18, 2013
P3, N=1053, Completed, Sponsor: Taro Pharmaceuticals USA
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  clotrimazole topical / Generic mfg.
Trial completion:  Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra (clinicaltrials.gov) -  Dec 18, 2013
P1, N=707, Completed,  Sponsor: Taro Pharmaceuticals USA
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis (clinicaltrials.gov) - Dec 18, 2013
P1, N=661, Completed, Sponsor: Taro Pharmaceuticals USA
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  BI 655064 / AbbVie, Boehringer Ingelheim
New P1 trial:  Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) -  Dec 10, 2013
P1, N=10, Recruiting,  Sponsor: Boehringer Ingelheim

|||||||||| New P2 trial: Evaluating the Effect of Senna in Uremic Pruritus (clinicaltrials.gov) - Dec 9, 2013
P2, N=62, Completed, Sponsor: Shiraz University of Medical Sciences

||||||||||  tradipitant (VLY-686) / Vanda
Enrollment open:  Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis (clinicaltrials.gov) -  Dec 8, 2013
P2, N=68, Recruiting,  Sponsor: Vanda Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  tradipitant (VLY-686) / Vanda
New P2 trial:  Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis (clinicaltrials.gov) -  Dec 4, 2013
P2, N=68, Recruiting,  Sponsor: Vanda Pharmaceuticals

|||||||||| Enrollment open: Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) (clinicaltrials.gov) - Nov 7, 2013
P1, N=64, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting

||||||||||  lovastatin / Generic mfg.
New P2 trial:  NeuSTART2: Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2 (clinicaltrials.gov) -  Nov 4, 2013
P2, N=168, Recruiting,  Sponsor: Mitchell S Elkind

||||||||||  Doptelet (avatrombopag) / SOBI
Enrollment change:  A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501 (clinicaltrials.gov) -  Oct 30, 2013
P1, N=28, Completed,  Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting N=23 --> 28

||||||||||  Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
Trial termination:  A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) (clinicaltrials.gov) -  Oct 29, 2013
P3, N=24, Terminated,  Sponsor: Eisai Inc.
N=23 --> 28 Recruiting --> Terminated; Study was terminated early due to significant enrollment challenges.

||||||||||  Doptelet (avatrombopag) / SOBI
Enrollment change:  Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) (clinicaltrials.gov) -  Oct 29, 2013
P3, N=49, Completed,  Sponsor: Eisai Inc.
Recruiting --> Terminated; Study was terminated early due to significant enrollment challenges. N=100 --> 49

||||||||||  Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
Enrollment change:  A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) (clinicaltrials.gov) -  Oct 29, 2013
P3, N=24, Terminated,  Sponsor: Eisai Inc.
N=100 --> 49 N=350 --> 24

||||||||||  lovastatin / Generic mfg.
Enrollment open:  NeuSTART2: Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2 (clinicaltrials.gov) -  Oct 29, 2013
P2, N=168, Recruiting,  Sponsor: Mitchell S Elkind
N=350 --> 24 Not yet recruiting --> Recruiting

|||||||||| New P1 trial: Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) (clinicaltrials.gov) - Oct 14, 2013
P1, N=64, Recruiting, Sponsor: Merck Sharp & Dohme Corp.

||||||||||  REGN846 / Regeneron
Trial termination:  Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis (clinicaltrials.gov) -  Sep 26, 2013
P1/2, N=19, Terminated,  Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Completed --> Terminated

||||||||||  Naftin (naftifine hydrochloride) / Merz Pharma
Trial completion:  Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis (clinicaltrials.gov) -  Sep 12, 2013
P4, N=65, Completed,  Sponsor: Merz Pharmaceuticals, LLC
Completed --> Terminated Recruiting --> Completed

|||||||||| Trial withdrawal: Gabapentin for the Treatment of Pruritus Caused by Burn Injuries in Children (clinicaltrials.gov) - Aug 18, 2013
P1, N=0, Withdrawn, Sponsor: The Hospital for Sick Children
Recruiting --> Completed Recruiting --> Withdrawn



	Diseases Companies Products Productz Mechanisms of Action Sites